WallStreetZenWallStreetZen

NYSE: BHVN
Biohaven Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BHVN

Based on 9 analysts offering 12 month price targets for Biohaven Ltd

Min Forecast
$9.00-8.91%
Avg Forecast
$16.89+70.94%
Max Forecast
$30.00+203.64%

Should I buy or sell BHVN stock?

Based on 9 analysts offering ratings for Biohaven Ltd.

Strong Buy
Strong Buy
5 analysts 55.56%
Buy
1 analysts 11.11%
Hold
3 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BHVN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BHVN as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their BHVN stock forecasts and price targets.

BHVN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-02
lockedlocked$00.00+00.00%2026-03-11
lockedlocked$00.00+00.00%2026-03-04
lockedlocked$00.00+00.00%2026-03-03
lockedlocked$00.00+00.00%2026-01-06
UBS
Top 15%
86
HoldDowngrades$11.00+11.34%2025-11-26
JP Morgan
Top 15%
86
Strong BuyMaintains$15.00+51.82%2025-11-20
BTIG
Bottom 8%
8
Strong BuyReiterates$16.00+61.94%2025-11-18
Bernstein
Bottom 12%
12
HoldDowngrades$9.00-8.91%2025-11-06

1 of 1

Forecast return on equity

Is BHVN forecast to generate an efficient return?

Company
-149.31%
Industry
65.32%
Market
171.88%
BHVN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BHVN forecast to generate an efficient return on assets?

Company
-17.22%
Industry
30.14%
BHVN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BHVN earnings per share forecast

What is BHVN's earnings per share in the next 3 years based on estimates from 20 analysts?

Avg 1 year Forecast
-$2.94
Avg 2 year Forecast
-$2.45
Avg 3 year Forecast
-$1.84

BHVN revenue forecast

What is BHVN's revenue in the next 3 years based on estimates from 20 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$40.4M
Avg 3 year Forecast
$124.4M

BHVN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BHVN$9.88$16.89+70.94%Strong Buy
IMCR$29.30$59.83+104.21%Buy
AGIO$25.32$38.88+53.53%Buy
BCAX$22.65$27.00+19.21%Buy
DMRA$24.75$43.40+75.35%Strong Buy
View Top Biotech Stocks

Biohaven Stock Forecast FAQ

Is Biohaven Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NYSE: BHVN) stock is to Strong Buy BHVN stock.

Out of 9 analysts, 5 (55.56%) are recommending BHVN as a Strong Buy, 1 (11.11%) are recommending BHVN as a Buy, 3 (33.33%) are recommending BHVN as a Hold, 0 (0%) are recommending BHVN as a Sell, and 0 (0%) are recommending BHVN as a Strong Sell.

If you're new to stock investing, here's how to buy Biohaven stock.

What is BHVN's earnings growth forecast for 2026-2028?

(NYSE: BHVN) Biohaven's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.63%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.53%.

Biohaven's earnings in 2026 is -$738,822,000.On average, 20 Wall Street analysts forecast BHVN's earnings for 2026 to be -$441,564,392, with the lowest BHVN earnings forecast at -$582,264,532, and the highest BHVN earnings forecast at -$314,296,497. On average, 20 Wall Street analysts forecast BHVN's earnings for 2027 to be -$367,995,396, with the lowest BHVN earnings forecast at -$538,041,909, and the highest BHVN earnings forecast at -$247,962,563.

In 2028, BHVN is forecast to generate -$276,917,852 in earnings, with the lowest earnings forecast at -$495,293,374 and the highest earnings forecast at -$15,793,794.

What is BHVN's revenue growth forecast for 2026-2028?

(NYSE: BHVN) Biohaven's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.3%.

Biohaven's revenue in 2026 is $0.On average, 20 Wall Street analysts forecast BHVN's revenue for 2026 to be $0, with the lowest BHVN revenue forecast at $0, and the highest BHVN revenue forecast at $0. On average, 19 Wall Street analysts forecast BHVN's revenue for 2027 to be $6,070,382,259, with the lowest BHVN revenue forecast at $0, and the highest BHVN revenue forecast at $15,793,793,820.

In 2028, BHVN is forecast to generate $18,710,381,079 in revenue, with the lowest revenue forecast at $3,632,121,327 and the highest revenue forecast at $60,720,368,469.

What is BHVN's forecast return on assets (ROA) for 2026-2029?

(NYSE: BHVN) forecast ROA is -17.22%, which is lower than the forecast US Biotechnology industry average of 30.14%.

What is BHVN's Price Target?

According to 9 Wall Street analysts that have issued a 1 year BHVN price target, the average BHVN price target is $16.89, with the highest BHVN stock price forecast at $30.00 and the lowest BHVN stock price forecast at $9.00.

On average, Wall Street analysts predict that Biohaven's share price could reach $16.89 by Apr 2, 2027. The average Biohaven stock price prediction forecasts a potential upside of 70.94% from the current BHVN share price of $9.88.

What is BHVN's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: BHVN) Biohaven's current Earnings Per Share (EPS) is -$6.86. On average, analysts forecast that BHVN's EPS will be -$2.94 for 2026, with the lowest EPS forecast at -$3.87, and the highest EPS forecast at -$2.09. On average, analysts forecast that BHVN's EPS will be -$2.45 for 2027, with the lowest EPS forecast at -$3.58, and the highest EPS forecast at -$1.65. In 2028, BHVN's EPS is forecast to hit -$1.84 (min: -$3.29, max: -$0.11).

What is BHVN's forecast return on equity (ROE) for 2026-2029?

(NYSE: BHVN) forecast ROE is -149.31%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.